We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03847376
Expanded Access Status : Approved for marketing
First Posted : February 20, 2019
Last Update Posted : April 5, 2021
Sponsor:
Collaborator:
ViiV Healthcare
Information provided by (Responsible Party):
Janssen Sciences Ireland UC

Tracking Information
First Submitted Date February 18, 2019
First Posted Date February 20, 2019
Last Update Posted Date April 5, 2021
 
Descriptive Information
Brief Title Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection
Official Title Rilpivirine Long Acting Single Patient Requests
Brief Summary The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus (HIV)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the Phase III clinical studies or do not qualify). RPV LA can only be provided if participants are also eligible for cabotegravir Long Acting injections.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition HIV
Intervention Drug: Rilpivirine Long Acting (RPV LA)
Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter [mL] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
Other Name: JNJ-16150108-AAA
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Approved for marketing
Eligibility Criteria Not Provided
Sex/Gender Not Provided
Ages Child, Adult, Older Adult
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03847376
Other Study ID Numbers CR108331
TMC278LAHTX2001 ( Other Identifier: Janssen Sciences Ireland UC )
Current Responsible Party Janssen Sciences Ireland UC
Original Responsible Party Same as current
Current Study Sponsor Janssen Sciences Ireland UC
Original Study Sponsor Same as current
Collaborators ViiV Healthcare
Investigators
Study Director: Janssen Sciences Ireland UC Clinical Trial Janssen Sciences Ireland UC
PRS Account Janssen Sciences Ireland UC
Verification Date March 2021